Wei Jing, Jiao Fangzheng, Wang Xiaoya, Qiao Yifan, Yuan Zihan, Liu Fang, Fang Yan, Pan Yanfang
Department of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang, China.
Department of Clinical Medicine, Yan'an University School of Medicine, Yan'an, China.
Clin Med Insights Oncol. 2024 Nov 29;18:11795549241301341. doi: 10.1177/11795549241301341. eCollection 2024.
Breast cancer (BRCA), the hormone related malignant tumor, is well-known for poor prognosis. ZNF208 mainly acts as a transcription factor in various tumors, and the single nucleotide polymorphisms (SNPs) of ZNF208 are related to telomere length. Nevertheless, its role in breast tumorigenesis is largely unknown.
We systematically investigated the gene expression, prognostic value, and promoter methylation of in BRCA with Gene Expression Profiling Interactive Analysis (GEPIA) and DNA Methylation Interactive Visualization Database (DNMIVD). Meanwhile, we clarified the association of ZNF208 with tumor-infiltrating immune cells (TICs) from Tumor Immune Estimation Resource (TIMER). Furthermore, we determined the biological process and functional enrichment from Cancer single-cell state atlas (CancerSEA). Finally, we verified our results with prognostic analysis and immunohistochemistry (IHC) assay.
We discovered that ZNF208 was downregulated in breast cancer, and low expression of ZNF208 predicted worse prognosis of BRCA patients. The promoter methylation level of was obviously increased, and ZNF208 was associated with TlCs in BRCA. In addition, ZNF208 could inhibit the metastasis and invasion biological processes, and regulate the MAPK and RAS signaling pathways in BRCA.
Our findings illustrate that ZNF208 can function as a tumor suppressor and predict prognosis of breast cancer.
乳腺癌(BRCA)是一种激素相关的恶性肿瘤,以预后不良而闻名。ZNF208在多种肿瘤中主要作为转录因子发挥作用,并且ZNF208的单核苷酸多态性(SNP)与端粒长度相关。然而,其在乳腺肿瘤发生中的作用在很大程度上尚不清楚。
我们使用基因表达谱交互式分析(GEPIA)和DNA甲基化交互式可视化数据库(DNMIVD)系统地研究了BRCA中ZNF208的基因表达、预后价值和启动子甲基化。同时,我们通过肿瘤免疫评估资源(TIMER)阐明了ZNF208与肿瘤浸润免疫细胞(TIC)的关联。此外,我们从癌症单细胞状态图谱(CancerSEA)确定了生物学过程和功能富集。最后,我们通过预后分析和免疫组织化学(IHC)检测验证了我们的结果。
我们发现ZNF208在乳腺癌中表达下调,ZNF208的低表达预示着BRCA患者的预后更差。ZNF208的启动子甲基化水平明显升高,并且ZNF208与BRCA中的TIC相关。此外,ZNF208可以抑制BRCA中的转移和侵袭生物学过程,并调节MAPK和RAS信号通路。
我们的研究结果表明ZNF208可以作为一种肿瘤抑制因子,并预测乳腺癌的预后。